MedPath

Vitamin D, Glucose Control and Insulin Sensitivity in African-Americans

Phase 2
Completed
Conditions
Type 2 Diabetes
Interventions
Dietary Supplement: cholecalciferol
Other: microcrystalline cellulose
Registration Number
NCT00784511
Lead Sponsor
Tufts University
Brief Summary

North American blacks tend to have low blood levels of vitamin D because pigmentation blocks vitamin D production in the skin. They also have higher rates of developing type 2 diabetes and higher rates of complications from the disease compared with whites. Although there is compelling evidence that adequate vitamin D may reduce the risk for type 2 diabetes in whites, recent evidence from a national survey demonstrated an association of vitamin D with diabetes in whites but not in blacks. However, the central hypothesis of this study is that providing enough supplemental vitamin D to blacks (raising their blood levels higher than that of most participants in the survey) will improve blood measures related to diabetes risk. The proposed study is a 12-week randomized, double-blind, placebo-controlled experiment designed to examine the effect of vitamin D supplementation (100 μg/d ) on insulin secretion, insulin sensitivity and glucose control in pre-diabetic black men and women aged 40 and older.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
100
Inclusion Criteria
  • African-American by self designation
  • Glucose intolerance defined as FPG ≥ 100 mg/dl or A1c ≥ 5.8%
  • BMI 25.0-39.9
  • Age 40 or older
Read More
Exclusion Criteria

Medical Conditions

  • Diabetes potentially requiring pharmacotherapy, defined as A1c > 7%

  • Uncontrolled thyroid disease

  • Current parathyroid, liver or kidney disease

  • Renal stone within 5 years

  • Sarcoidosis, current pancreatitis, active tuberculosis, hemiplegia, gout

  • Inflammatory bowel disease, colostomy, malabsorption

  • Cancer other than basal cell skin cancer within 5 years

  • Uncontrolled arrhythmia in past year

  • Albinism or other condition associated with reduced skin pigmentation

  • Pregnancy over the last 1 year

  • Intent to become pregnant

  • Menopause onset within 1 year

  • Any other unstable medical condition Laboratory Tests

  • Fasting plasma glucose < 100

  • Hemoglobin A1c > 7%

  • Laboratory evidence of liver disease (e.g. AST > 70 U/L or ALT > 72 IU/L)

  • Laboratory evidence of kidney disease (e.g. estimated glomerular filtration rate < 60 ml/min/1.73 m2).

  • Elevated spot urine calcium to creatinine ratio > 0.38 mg/dl*

  • Abnormal serum calcium (serum calcium > 10.5 mg/dl)

  • Anemia (Hematocrit < 36% in men, <33% in women) Medications (use in past three months)

  • Estrogen or testosterone

  • Prescription vitamin D

  • Lithium

  • Oral corticosteroids

  • Anti-seizure medications

  • Unstable doses of psychotropics or phenothiazines

  • Cholestyramine Supplements (current use - may discontinue after screening)

  • Vitamin D supplements, cod liver oil, calcium supplements Other

  • Body mass index less <25 or > 39.9

  • Consumption of more than 14 alcoholic drinks per week

  • Inability to attend all three study visits as scheduled

  • Inability to provide written informed consent

  • age < 40 years

  • not African-American (by self-designation)

  • Participation in another research intervention study

    • corresponds to a 24-hour urinary calcium excretion > 400 mg
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
1 vitamin D3cholecalciferolvitamin D3, 4000 IU/d
2microcrystalline celluloseplacebo
Primary Outcome Measures
NameTimeMethod
Insulin secretion rate12 weeks
Insulin sensitivity index12 weeks
2-hr post load glucose12 weeks
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University

🇺🇸

Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath